Early cancer vaccines were primarily focused on stimulating CD8+ T cell responses against tumor associated antigens often using short minimal epitope sequences, T cells recognizing these antigens are highly tolerized and subsequently these vaccines fail in the clinic. This evidence concerns the gene CD8A and cancer.